Neuroacanthocytosis
dc.contributor.author | Feriante, Joshua | |
dc.contributor.author | Gupta, Vikas | |
dc.date | 2022-08-11T08:09:57.000 | |
dc.date.accessioned | 2022-08-23T16:50:24Z | |
dc.date.available | 2022-08-23T16:50:24Z | |
dc.date.issued | 2020-10-05 | |
dc.date.submitted | 2020-12-29 | |
dc.identifier.citation | <p>Feriante J, Gupta V. Neuroacanthocytosis. 2020 Oct 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32809602. <a href="https://www.ncbi.nlm.nih.gov/books/NBK560767/" target="_blank" title="book chapter in PMC">Link to book chapter in PMC</a></p> | |
dc.identifier.pmid | 32809602 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/41652 | |
dc.description.abstract | Neuroacanthocytosis refers to a group of inherited genetic disorders resulting in a combination of misshapen red blood cells (acanthocytes) and progressive neurological decline.[1] The neurological presentation can vary widely among diseases and can include shared characteristic features of movement disorders, neuropathy, psychiatric symptoms, neurocognitive degeneration, and seizures.[2] Specific diseases are many, including chorea-acanthocytosis (ChAc),[3] McLeod syndrome (MLS),[4] Huntington like-disease 2 (HDL2),[5] pantothenate kinase-associated neurodegeneration (PKAN, also known as Hallervorden Spatz disease),[6][7] HARP Syndrome (considered part of the PKAN spectrum consisting of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration), abetalipoproteinemia (ABL),[8] hereditary hypobetalipoproteinemia (HHBL),[9] and aceruloplasminemia.[10][11] The two core conditions are chorea-acanthocytosis and McLeod Syndrome. Each neuroacanthocytosis disorder is extremely rare, with a prevalence of less than 1 to 3 per 1,000,000 individuals for PKAN or fewer than 100 cases ever reported in the case of ABL. | |
dc.language.iso | en_US | |
dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32809602&dopt=Abstract" target="_blank" title="book chapter in PubMed">Link to Book Chapter in PubMed</a></p> | |
dc.relation.url | https://www.ncbi.nlm.nih.gov/books/NBK560767/ | |
dc.rights | Copyright © 2020, StatPearls Publishing LLC. This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated. | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Neuroacanthocytosis | |
dc.subject | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | |
dc.subject | Nervous System Diseases | |
dc.title | Neuroacanthocytosis | |
dc.type | Book Chapter | |
dc.source.booktitle | StatPearls | |
dc.identifier.legacyfulltext | https://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5473&context=oapubs&unstamped=1 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/4443 | |
dc.identifier.contextkey | 20858376 | |
refterms.dateFOA | 2022-08-23T16:50:24Z | |
html.description.abstract | <p>Neuroacanthocytosis refers to a group of inherited genetic disorders resulting in a combination of misshapen red blood cells (acanthocytes) and progressive neurological decline.[1] The neurological presentation can vary widely among diseases and can include shared characteristic features of movement disorders, neuropathy, psychiatric symptoms, neurocognitive degeneration, and seizures.[2] Specific diseases are many, including chorea-acanthocytosis (ChAc),[3] McLeod syndrome (MLS),[4] Huntington like-disease 2 (HDL2),[5] pantothenate kinase-associated neurodegeneration (PKAN, also known as Hallervorden Spatz disease),[6][7] HARP Syndrome (considered part of the PKAN spectrum consisting of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration), abetalipoproteinemia (ABL),[8] hereditary hypobetalipoproteinemia (HHBL),[9] and aceruloplasminemia.[10][11] The two core conditions are chorea-acanthocytosis and McLeod Syndrome. Each neuroacanthocytosis disorder is extremely rare, with a prevalence of less than 1 to 3 per 1,000,000 individuals for PKAN or fewer than 100 cases ever reported in the case of ABL.</p> | |
dc.identifier.submissionpath | oapubs/4443 | |
dc.contributor.department | Department of Psychiatry |